Binds Enzyme Patents (Class 530/388.26)
-
Publication number: 20110213129Abstract: This invention relates to the PrtR-PrtK cell surface protein of Porphyromonas gingivalis and in particular a multimeric cell association protein complex comprising the PrtR and PrtK proteins. Accordingly the invention provides a substantially purified antigenic complex for use in raising an antibody response directed against Porphyromonas gingivalis. The complex comprises at least one multimeric protein complex of arginine-specific and lysine-specific thiol endopeptidases each containing at least one adhesin domain, the complex having a molecular weight of greater than about 200 kDa. The invention also relates to pharmaceutical compositions and associated agents based on said complex for the detection, prevention and treatment of Periodontal disease associated with P. gingivalis.Type: ApplicationFiled: March 16, 2011Publication date: September 1, 2011Applicant: The University of MelbourneInventors: Eric Charles Reynolds, Peter Singh Bhogal, Nada Slakeski
-
Patent number: 8008452Abstract: The present invention relates to the phosphorylated form of nuclear serine/threonine protein kinase, designated nuclear, Dbf2-related kinase (Ndr), and provides assays and materials for identifying modulators thereof. The invention relates to the fields of molecular biology, chemistry, pharmacology, and screening technology.Type: GrantFiled: November 25, 2003Date of Patent: August 30, 2011Assignee: Novartis Forschungesstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical ResearchInventors: Samuel Joseph Bichsel, Brian Arthur Hemmings, Mario Reinhard Stegert, Rastislav Tamaskovic
-
Patent number: 7994291Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3? ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.Type: GrantFiled: May 25, 2010Date of Patent: August 9, 2011Assignee: Amgen Inc.Inventors: Hui-Quan Han, Keith Kwak
-
Publication number: 20110191875Abstract: The invention provides compositions and methods for producing androstenedione (4-androstenedione), of improved purity and for modulating its production, for example by deletion or inactivation of ksdA, cxgA, cxgB, cxgC, or cxgD. The invention also provides methods and compositions, including nucleic acids that encode enzymes, for producing 1,4-androstadiene-3,17-dione (ADD) and related pathway compounds, including 20-(hydroxymethyl)pregna-4-en-3-one and 20-(hydroxymethyl)pregna-1,4-dien-3-one. The compositions of the invention include nucleic acids, probes, vectors, cells, transgenic plants and seeds, transgenic animals, kits and arrays.Type: ApplicationFiled: November 13, 2008Publication date: August 4, 2011Applicant: Verenium CorporationInventors: David Nunn, Catherine Pujol, Kelly Chatman
-
Patent number: 7989597Abstract: This application pertains to antibodies which specifically bind to immunogenic memapsin 2?-secretase peptides for use in the treatment of Alzheimer's disease and memapsin 2?-secretase disorders. The application also pertains to immunogenic compositions comprising memapsin 2?-secretase peptides and uses thereof.Type: GrantFiled: June 22, 2009Date of Patent: August 2, 2011Assignee: Oklahoma Medical Research FoundationInventors: Wan-Pin Chang, Jordan Tang
-
Patent number: 7977314Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1.Type: GrantFiled: March 5, 2007Date of Patent: July 12, 2011Assignee: Amorfix Life Sciences LimitedInventor: Neil R. Cashman
-
Patent number: 7973142Abstract: Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTP?), and uses thereof.Type: GrantFiled: April 5, 2007Date of Patent: July 5, 2011Assignee: Warner Chilcott CompanyInventors: Rocco Jamie Rotello, Kevin Gene Peters, Michael Glenn Davis
-
Patent number: 7973143Abstract: Compositions, methods and kits for diagnosing and treating cancer are provided. Therapeutic compositions may comprise agents that modulate the expression or activity of a sphingosine-1-phosphate lyase (SPL). Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous SPL. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided.Type: GrantFiled: December 22, 2008Date of Patent: July 5, 2011Assignee: Children's Hospital & Research Center at OaklandInventors: Julie D. Saba, Jianhui Zhou
-
Patent number: 7960513Abstract: Elucidation of the crystal structure of an ADAM10 substrate-recognition and proteinase-positioning module comprising the protein cysteine-rich and disintegrin domains, and detailed functional analysis revealed that an acidic pocket within the cysteine-rich domain forms a substrate-recognition site. The binding of this pocket to receptor/ligand complexes facilitates effective ligand cleavage, which is prevented when critical residues within the pocket are changed. This provides use of the surface pocket within the extracellular domain of ADAM10, and the corresponding structure in related proteases such as ADAM17, as a target for structure-based computational and high-throughput screens for small-molecule substrate-specific inhibitors or monoclonal antibodies that inhibit ADAM protease cleavage of ephrins and other ADAM10 or ADAM17 substrates.Type: GrantFiled: December 19, 2005Date of Patent: June 14, 2011Assignees: Monash University, Memorial Sloan Kettering Cancer CenterInventors: Martin Lackmann, Peter W. Janes, Dimitar B. Nikolov, Nayanendu Saha
-
Publication number: 20110136232Abstract: This document provides methods and materials related to anti-Pyk2 antibodies. For example, anti-Pyk2 antibodies, methods for making anti-Pyk2 antibodies, and methods for using an anti-Pyk2 antibody to inhibit glioma cell migration are provided.Type: ApplicationFiled: May 28, 2009Publication date: June 9, 2011Inventors: Christopher A. Lipinski, Joseph C. Loftus
-
Publication number: 20110124021Abstract: The disclosed invention relates to the detection of phosphorylated fatty acid synthase as a diagnostic and a component in the identification and treatment of cancer. The disclosed methods permit early and accurate diagnosis of cancer to enable more effective therapy and to enhance patient survival and quality of life.Type: ApplicationFiled: November 13, 2008Publication date: May 26, 2011Inventor: Susan Medghalchi
-
Publication number: 20110123528Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.Type: ApplicationFiled: January 14, 2011Publication date: May 26, 2011Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
-
Patent number: 7939280Abstract: Use of pregnancy-associated plasma protein-A as a marker for inflammatory conditions, and in particular, for acute coronary syndromes is described.Type: GrantFiled: May 24, 2010Date of Patent: May 10, 2011Assignee: Mayo Foundation for Medical Education and ResearchInventors: Cheryl A Conover, Antonio Bayes-Genis, David R Holmes, Robert S Schwartz
-
Patent number: 7939282Abstract: Compositions and methods for detecting sepsis by contacting a subject-derived sample with a ligand that binds to GRK and determining the concentration of GRK in the sample. An increase in the concentration of GRK compared to that of a normal, healthy control sample indicates that the subject from which the sample is obtained is suffering from or at risk of developing sepsis.Type: GrantFiled: October 20, 2005Date of Patent: May 10, 2011Assignee: Rhode Island HospitalInventors: Loren D. Fast, Yow-Pin Lim
-
Publication number: 20110105731Abstract: Provided herein are antibodies, fragments and derivatives of an antibody containing a binding domain thereof, where the antibody, fragment or derivative specifically binds to a single chain protease domain of a type II transmembrane serine protease (MTSP). Methods using the antibodies to modulate the protease activity of an MTSP are provided. Also provided are antibodies that bind to MTSPs designated MTSP3 and MTSP4 and to a form of an MTSP designated MTSP6.Type: ApplicationFiled: November 12, 2010Publication date: May 5, 2011Inventors: Edwin L. Madison, Edgar O. Ong, Jiunn-Chern Yeh
-
Publication number: 20110091477Abstract: The invention provides methods and compositions for modulating hepatocyte growth factor activator function.Type: ApplicationFiled: October 18, 2010Publication date: April 21, 2011Applicant: Genentech, Inc.Inventors: Rajkumar Ganesan, Daniel Kirchhofer
-
Patent number: 7906297Abstract: The invention discloses two novel phosphorylation sites in human ATR kinase, serine 428 (Ser428) and serine 2317 (Ser2317) respectively, and provides reagents, including antibodies and AQUA peptides, that selectively bind to and/or detect ATR only when phosphorylated at one or more of these respective sites, but do not bind to ATR when not phosphorylated at these respective sites. Also provided are methods for determining the phosphorylation of ATR kinase in a biological sample, by using a detectable reagent that binds to ATR only when phosphorylated at Ser428 and/or Ser2317. Kits comprising the ATR (Ser428, Ser2317)-specific reagents of the invention are also provided.Type: GrantFiled: July 17, 2006Date of Patent: March 15, 2011Assignee: Cell Signaling Technology, Inc.Inventors: Mark Livingstone, Hong Ruan, Robert Polakiewicz
-
Patent number: 7902340Abstract: The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma.Type: GrantFiled: April 27, 2007Date of Patent: March 8, 2011Assignee: Delenex Therapeutics AGInventors: Adrian Auf Der Maur, Alcide Barberis, Peter Lichtlen
-
Publication number: 20110053221Abstract: The present invention relates to novel expression cassettes and vectors for efficiently producing authentic recombinant human proteins from stable cultures of novel human cell lines, the authentic recombinant proteins produced therefrom, and antibodies raised against those authentic recombinant proteins.Type: ApplicationFiled: March 12, 2009Publication date: March 3, 2011Inventors: Ridong Chen, Soon Seog Jeong, Hui Feng
-
Publication number: 20110023135Abstract: The use of the human or animal MCM9 gene, or parts of the gene, or transcripts thereof, or antisense nucleic acids able to hybridize with part of the gene or transcripts, or silencing RNA derived from parts of the transcripts and able to repress the MCM9 gene, or proteins or peptidic fragments translated from the transcripts, or antibodies directed against the proteins or peptidic fragments, for the preparation of a pharmaceutical composition for the treatment of a human or animal pathology linked to a dysfunction of the expression of the MCM9 gene, or of human or animal cancers.Type: ApplicationFiled: May 12, 2006Publication date: January 27, 2011Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Marcel Mechali, Domenico Maiorano, Malik Lutzmann
-
Publication number: 20100330092Abstract: A neutralizing monoclonal antibody specifically reacting with MMP13, a method of neutralizing enzyme activity of MMP13 and an immunological measuring method each using the antibody, as well as a diagnostic agent and a pharmaceutical composition containing the antibody, are provided. Various antibodies to MMP13 have been hitherto obtained, but an antibody having neutralizing activity against MMP13 has not been obtained. The present inventors intensively studied, as a result, found out a neutralizing antibody having specificity for MMP13, resulting in completion of the present invention.Type: ApplicationFiled: July 8, 2008Publication date: December 30, 2010Applicant: SHIONLGI & CO., LTD.Inventors: Shoichi Naito, Junji Onoda, Akira Yamauchi, Yoshito Numata, Junji Kishono
-
Publication number: 20100323908Abstract: Methods, compositions and kits for diagnosing osteoarthritis in a feline are disclosed. The methods of the invention comprise detecting differential expression of at least one biomarker in a body sample. preferably a blood sample, where the biomarker is differentially expressed in osteoarthritis.Type: ApplicationFiled: May 1, 2008Publication date: December 23, 2010Applicant: Hill's Pet Nutrition, Inc.Inventors: Samer Waleed Khedheyer Al-Murrani, William David Schoenherr
-
Publication number: 20100317835Abstract: A remedy for cancer obtained from a different viewpoint from the viewpoints employed in developing the existing anticancer drugs, i.e., focusing on the intercellular adhesion of cancer cells. Namely, provided is a remedy for cancer with fewer side effects which inhibits the proliferation of cancer cells and the intercellular adhesion of cancer cells. Also provided is an antibody, which recognizes the disintegrin domain of ADAM-15 and is usable as an anticancer agent, and so on. An antibody, which recognizes the disintegrin domain of ADAM-15 but does not recognize the RGD sequence or loop region in the disintegrin domain of ADAM-15, and so on; an antibody, which inhibits ADAM-15 and integrin ?v?3-dependent cell adhesion, and so on; and an antibody, which inhibits ADAM-15 and integrin ?v?1-dependent cell adhesion, and so on.Type: ApplicationFiled: February 12, 2009Publication date: December 16, 2010Inventors: Toshimitsu Uede, Yutaka Matsui
-
Patent number: 7846673Abstract: Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) found in body fluids, such as, urine and serum. Soluble CA IX comprises the extracellular domain of CA IX or portions thereof. The predominant s-CA IX species is the extracellular domain comprising a proteoglycan-like (PG) domain and carbonic anhydrase (CA) domain, and having a molecular weight of about 50/54 kilodaltons. Diagnostic/prognostic methods for precancer/cancer that detect or detect and quantitate s-CA IX in body fluids, are described. Also disclosed is the coexpression of CA IX and HER-2 that provides potentially synergistic diagnostic/prognostic and therapeutic strategies for precancer/cancer. Further disclosed are new MN/CA IX-specific antibodies generated from MN/CA IX-deficient mice, useful diagnostically/prognostically and therapeutically for cancer/precancer.Type: GrantFiled: August 19, 2004Date of Patent: December 7, 2010Assignee: Institute of Virology of the Slovak Academy of SciencesInventors: Jaromir Pastorek, Silvia Pastorekova, Miriam Zatovicova, Jan Zavada, Marta Ortova Gut, Zuzanna Zavadova
-
Patent number: 7829095Abstract: A monoclonal antibody which inhibits the blood clotting factor VII-activating protease and its proenzyme and a blood clotting factor VII-activating protease, stabilized by the addition of said monoclonal antibody, and its proenzyme are described. A suitable monoclonal antibody is produced by hybridoma cell line DSM ACC 2533. The application of the inhibitory, monoclonal antibody in the stabilization of blood clotting preparations and in preparations for reducing the coagulability of the blood is disclosed.Type: GrantFiled: February 7, 2003Date of Patent: November 9, 2010Assignee: CSL Behring GmbHInventors: Juergen Roemisch, Wiegand Lang, Annette Feussner, Gudrun Muth-Naumann, Hans-Arnold Stoehr, Christian Kannemaier, Klaus Preissner, Fumie Nakazawa
-
Patent number: 7824682Abstract: The present disclosure provides a cDNA, protein sequence, and genomic structure of the human cardiac isoform of myosin light chain kinase (cMLCK), and describes mutations in the cMLCK gene that are associated with cardiac dysfunction. Methods are provided for identifying individuals who can harbor mutations in the cMLCK gene, or carry alleles that can predisposed them to cardiac dysfunction. Disclosed also is a significant role for cMLCK in modulating cardiac contractility. The cMLCK protein is shown herein to reduce the amplitude of stretch activation and increase the tension production, a property of muscle which has heretofore had an unknown role in cardiac contraction. Moreover, the cMLCK protein is shown to be regionally distributed in the heart, thereby having differential effects on contractility and stretch activation. Methods herein are provided to exploit this effect of cMLCK, to treat individuals who have or are prone to cardiac dysfunction.Type: GrantFiled: April 11, 2008Date of Patent: November 2, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Neal D. Epstein, Shahin Hassanzadeh, Steve O. Winitsky, Julien S. Davis
-
Patent number: 7824876Abstract: A bioaffinity assay for quantitative determination in a sample of free PAPP-A, defined as the pregnancy associated plasma protein A (PAPP-A) that is not complexed to the proform of major basic protein (proMBP), where free PAPP-A is determined either i) as a calculated difference between measured total PAPP-A and measured PAPP-A complexed to proMBP, or ii) by a direct bioaffinity assay measuring only free PAPP-A. Also disclosed is a method for diagnosing an acute coronary syndrome in a person by using as marker either free PAPP-A as such or a ratio free PAPP-A/total PAPP-A, free PAPP-A/PAPP-A complexed to proMBP, or PAPP-A complexed to proMBP/total PAPP-A.Type: GrantFiled: January 19, 2005Date of Patent: November 2, 2010Assignee: Turun YliopistoInventors: Qiu-Ping Qin, Kim Pettersson
-
Publication number: 20100273187Abstract: Disclosed are antibodies that specifically recognize ?5-desaturase, methods of producing the antibodies, nucleotides and polypeptides for producing the antibodies, and methods of using the antibodies. The ?5-desaturase-specific antibodies provide improved methods of detecting ?5-desaturase in a sample.Type: ApplicationFiled: January 13, 2010Publication date: October 28, 2010Applicant: ABBOTT LABORATORIESInventors: Tapas Das, Suzette L. Pereira, Pradip Mukerji, Padmavathy Krishnan
-
Patent number: 7820797Abstract: A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.Type: GrantFiled: July 3, 2008Date of Patent: October 26, 2010Assignee: University of Georgia Research Foundation, Inc.Inventor: Geert-Jan Boons
-
Publication number: 20100267131Abstract: Isolated nucleic acid molecules having a nucleotide sequence encoding feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Isolated feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Host cells comprising a vector containing the polynucleotide sequences and methods for expressing the polypeptides. The generation of monoclonal antibodies that specifically binds to the feline pancreatic lipase polypeptides, and cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of feline pancreatic lipase in a biological sample. The methods include using standards or calibrators of recombinant feline pancreatic lipase to quantify the lipase in a sample. Devices and kits for performing methods for detecting feline pancreatic lipase in biological samples.Type: ApplicationFiled: June 10, 2010Publication date: October 21, 2010Applicant: IDEXX LABORATORIES, INC.Inventors: Philip Andersen, Melissa Jane Beall, Jesse Buch, Ku-chuan Hsiao, Stacey Pazar Huth, Eugene Regis Krash, III, Barbara O'Brien, Marilyn Strong-Townsend
-
Patent number: 7816499Abstract: The present invention features, inter alia, purified antibodies that selectively bind an isolated or recombinant histone deacetylase polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 2, which comprises a histone deacetylase catalytic domain at amino acids 635 to 953 of SEQ ID NO: 2, purified antibodies that selectively bind a biologically active fragment of the polypeptide of SEQ ID NO: 2, which fragment exhibits histone deacetylase activity, transcription repression activity, and the ability to deacetylate cellular substrates, purified antibodies that selectively bind an isolated or recombinant histone deacetylase polypeptide encoded by a nucleotide sequence as set forth in SEQ ID NO: 1, purified antibodies that selectively bind an isolated or recombinant histone deacetylase polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 2 lacking a nuclear localization signal, and purified antibodies that selectively bind an isolated or recombinant histone deacetylase polypType: GrantFiled: May 31, 2007Date of Patent: October 19, 2010Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Victoria M. Richon, Xianbo Zhou, Richard A. Rifkind, Paul A. Marks
-
Publication number: 20100255000Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: ApplicationFiled: March 29, 2010Publication date: October 7, 2010Inventors: Uma Sinha, Genmin Lu, Pamela B. Conley
-
Patent number: 7799326Abstract: Methods and compositions for the amelioration of symptoms mediated by the collagenolytic activity of cathepsin K complex are provided. Methods of specifically modulating the collagenolytic activity of cathepsin K without substantial interference in other biologically-relevant activities of cathepsin K are further provided.Type: GrantFiled: September 24, 2002Date of Patent: September 21, 2010Assignee: Mount Sinai School of MedicineInventor: Dieter Bromme
-
Publication number: 20100233154Abstract: The invention relates to targeted binding agents that specifically bind to heparanase and inhibit the biological activity of heparanase and uses of such agents. More specifically the invention relates to fully human monoclonal antibodies directed to that specifically bind to heparanase and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The disclosed targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of heparanase.Type: ApplicationFiled: October 7, 2009Publication date: September 16, 2010Applicant: MedImmune LimitedInventors: Paul Elvin, Chadwick King, Palaniswami Rathanaswami
-
Publication number: 20100227335Abstract: Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MMP-7. Monoclonal antibodies having the binding characteristics of an MMP-7 antibody of the invention and monoclonal antibodies that bind to an MMP-7 epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce an MMP-7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed MMP-7 monoclonal antibodies and for practicing the methods of the invention are further provided.Type: ApplicationFiled: March 5, 2010Publication date: September 9, 2010Applicant: Becton, Dickinson and CompanyInventors: Jeffrey P. Baker, Robert L. Cheek, Eric P. Dixon, Timothy J. Fischer, Steven L. Knapp, Stephen G. Simkins, Clark M. Whitehead
-
Publication number: 20100226929Abstract: Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy.Type: ApplicationFiled: April 27, 2009Publication date: September 9, 2010Applicant: University of Iowa Research FoundationInventors: Mark E. Anderson, Peter J. Mohler, Douglas R. Spitz, JR., Jeffrey Robert Erickson
-
Patent number: 7771960Abstract: Isolated nucleic acid molecules having a nucleotide sequence encoding feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Isolated feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Host cells comprising a vector containing the polynucleotide sequences and methods for expressing the polypeptides. The generation of monoclonal antibodies that specifically binds to the feline pancreatic lipase polypeptides, and cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of feline pancreatic lipase in a biological sample. The methods include using standards or calibrators of recombinant feline pancreatic lipase to quantify the lipase in a sample. Devices and kits for performing methods for detecting feline pancreatic lipase in biological samples.Type: GrantFiled: October 15, 2008Date of Patent: August 10, 2010Assignee: IDEXX Laboratories, Inc.Inventors: Philip Andersen, Melissa Jane Beall, Jesse Buch, Ku-chuan Hsiao, Stacey Pazar Huth, Eugene Regis, Barbara O'Brien, Marilyn Strong-Townsend
-
Patent number: 7759466Abstract: Monoclonal antibody that specifically binds to alpha-amylase and is useful for detecting weather damage (i.e. pre-harvest sprouting) in cereal grain.Type: GrantFiled: June 1, 2006Date of Patent: July 20, 2010Assignee: Bayer CropScience AGInventor: John Howard Skerritt
-
Patent number: 7745586Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3? ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.Type: GrantFiled: August 6, 2008Date of Patent: June 29, 2010Assignee: Amgen Inc.Inventors: Hui-Quan Han, Keith Kwak
-
Patent number: 7745588Abstract: The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxillary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.Type: GrantFiled: August 7, 2007Date of Patent: June 29, 2010Assignee: BioProspecting NB Inc.Inventors: John M. Stewart, Bradley J. Steeves, Karl Vernes
-
Patent number: 7745587Abstract: Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.Type: GrantFiled: December 29, 2006Date of Patent: June 29, 2010Assignee: Dyax Corp.Inventors: Laetitia Devy, Henk Pieters, Robert C. Ladner, Rene Hoet, Daniel T. Dransfield, Clive R. Wood, Maria Henderikx
-
Publication number: 20100136113Abstract: This invention relates to phytases, polynucleotides encoding them, uses of the polynucleotides and polypeptides of the invention, as well as the production and isolation of such polynucleotides and polypeptides. In particular, the invention provides polypeptides having phytase activity under high temperature conditions, and phytases that retain activity after exposure to high temperatures. The phytases of the invention can be thermotolerant and/or thermostable at low temperatures, in addition to higher temperatures. The phytases of the invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients. The phytases of the invention can be formulated as foods or feeds or supplements for either to, e.g., aid in the digestion of phytate. The foods or feeds of the invention can be in the form of pellets, liquids, powders and the like.Type: ApplicationFiled: September 21, 2007Publication date: June 3, 2010Applicant: VERENIUM CORPORATIONInventors: Brian Steer, Mark Dycaico, Katie A. Kline, Axel Trefzer, Thomas Todaro, Arne Solbak, Fatima El-Farrah, Alberto Alvarado, Gerhard Frey
-
Patent number: 7723049Abstract: Use of pregnancy-associated plasma protein-A as a marker for inflammatory conditions, and in particular, for acute coronary syndromes is described.Type: GrantFiled: February 20, 2009Date of Patent: May 25, 2010Assignee: Mayo Foundation for Medical Education and ResearchInventors: Cheryl A. Conover, Antonio Bayes-Genis, David R. Holmes, Robert S. Schwartz
-
Patent number: 7722875Abstract: Isolated nucleic acid molecules having a nucleotide sequence encoding canine pancreatic lipase polypeptides, allelic variants and fragments thereof. Vectors and host cells containing the polynucleotide sequences and methods for expressing the polypeptides. Monoclonal antibodies that specifically binds to the canine pancreatic lipase polypeptides. Cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of canine pancreatic lipase in a biological sample. The methods include using the monoclonal antibodies to specifically bind to canine pancreatic lipase polypeptides. The method includes using standards of recombinant canine pancreatic lipase. Devices and kits for performing methods for detecting canine pancreatic lipase in biological samples.Type: GrantFiled: July 13, 2007Date of Patent: May 25, 2010Assignee: IDEXX Laboratories, Inc.Inventors: Melissa Beall, Stacey Pazar Huth, Eugene Regis Krah
-
Patent number: 7718777Abstract: Disclosed are protein ligands comprising an immunoglobulin heavy chain variable (VH) domain and an immunoglobulin light chain variable (VL) domain, wherein the proteins bind a complex comprising an MHC and a peptide, do not substantially bind the MHC in the absence of the bound peptide, and do not substantially bind the peptide in the absence of the MHC, and the peptide is a peptide fragment of gp100, MUC1, TAX, or hTERT. Also disclosed are methods of using and identifying such ligands.Type: GrantFiled: October 18, 2006Date of Patent: May 18, 2010Assignee: Technion Research & Development Foundation Ltd.Inventors: Henricus Renerus Jacobus Mattheus Hoogenboom, Yoram Reiter
-
Patent number: 7696328Abstract: This invention relates to isolated or recombinant N-carbobenzyloxy-deprotecting enzyme polypeptides that catalyze the removal of carbobenzyloxy from carbobenzyloxy-protected amino acids and alcohols. Also related are isolated nucleic acids encoding N-carbobenzyloxy-deprotecting enzyme polypeptides thereof, as well as vectors and host cells comprising these nucleic acids. The invention also relates to methods of obtaining isolated nucleic acids, polypeptides, and antibodies, and methods of using the polypeptides in various reactions for industrial or pharmaceutical applications.Type: GrantFiled: April 28, 2008Date of Patent: April 13, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Venkata B. Nanduri, Ramesh N. Patel, Steven L. Goldberg, Robert M. Johnston
-
Patent number: 7662929Abstract: Modulation of Hyaluronan (HA) synthesis and degradation is disclosed by compounds and compositions that are capable of reducing the level of hyaluronan synthase (HAS) or hyaluronidase (HYAL) or the function or activity of HAS or HYAL. The compounds and compositions can also inhibit the expression of genetic material encoding these enzymes. The compounds and compositions comprise nucleic acid molecules and interactive molecules such as antibodies, small molecule inhibitors and substrate analogs of HAS and HYAL. The compounds and compositions are useful in the prophylaxis and/or treatment of inflammatory disorders including hyperproliferative conditions, such as but not limited to, cancer and psoriasis.Type: GrantFiled: October 11, 2004Date of Patent: February 16, 2010Assignee: Alchemia Oncology Pty LimitedInventors: Tracey J. Brown, Gary R. Brownlee
-
Patent number: 7662769Abstract: The present invention provides a peptide or protein having a neovascularization action and containing a basic amino acid cluster region of ?1,6-N-acetylglucosaminyltransferase, a neovascularization accelerator containing the above-mentioned peptide or protein, a method of screening an inhibition substance for the above-mentioned peptide or protein, and a neovascularization inhibitor containing this inhibition substance.Type: GrantFiled: December 27, 2002Date of Patent: February 16, 2010Assignee: Suntory Holdings LimitedInventors: Naoyuki Taniguchi, Eiji Miyoshi, Takashi Saito
-
Publication number: 20090304685Abstract: A method is disclosed for preventing arterial thrombosis in a subject comprising administering to said subject a therapeutically effective amount of an antibody or epitope-binding fragment or derivative thereof, wherein said antibody, fragment or derivative specifically binds to activated Factor XIIa and prevents the interaction of activated Factor XIIa with its physiological substrates.Type: ApplicationFiled: April 12, 2007Publication date: December 10, 2009Inventor: David J. Pritchard
-
Patent number: 7611855Abstract: Using two types of antibodies, i.e., a first antibody having a higher affinity for a target substance than for a competitive substance and a second antibody having a higher affinity for the competitive substance than for the target substance, a specimen is treated with these two antibodies. Then, the competitive substance in the specimen first binds to the second antibody and thus the ratio of the target substance to the competitive substance in the specimen is enlarged. As a result, the target substance becomes liable to bind to the first antibody and, in its turn, the reactivity of the target substance is elevated compared with the case of using the first antibody alone. Thus, the target substance in the specimen can be accurately assayed while avoiding the effects of the competitive substance contained in the specimen.Type: GrantFiled: December 24, 2003Date of Patent: November 3, 2009Assignee: Nitto Boseki Co., Ltd.Inventors: Tatsuya Ohashi, Toshihide Miura, Yoshihiko Igarashi, Fumio Nomura, Takeshi Tomonaga, Katsuhiro Katayama